# Supplementary Material

## Supplementary Table S1. Details of search strategy used in Cochrane Database of Systematic Reviews search (01 January 2011–04 May 2017).

|  |  |
| --- | --- |
| # | SEARCH TERMS |
|  | Condition terms |
| 1 | (atrial fibrillation or AF or NVAF or AVAF).af. |
|  | Treatment terms |
| 2 | (new oral anticoagulants or novel oral anticoagulants or NOAC or non-vitamin K antagonists oral anticoagulants or nonvitamin K antagonists oral anticoagulants or DOAC or direct oral anticoagulants or Apixaban or Dabigatran or Rivaroxaban or Edoxaban or factor Xa inhibitor or TSOAC or TOAC or fxa inhibitor or direct thrombin inhibitor).af. |
| 3 | 1 and 2 [condition and treatment] |
| 4 | limit 3 to (full systematic reviews and last 6 years) |

## Supplementary Table S2. Details of search strategy used in Embase® search (01 January 2011–04 May 2017).

|  |  |
| --- | --- |
|  | SEARCH TERMS |
|  | **Condition terms** |
| 1 | (atrial fibrillation or AF or NVAF or AVAF).mp. |
| 2 | exp atrial fibrillation/  |
| 3 | 1 or 2 [condition] |
|  | **Treatment terms** |
| 4 | (new oral anticoagulants or novel oral anticoagulants or NOAC or non-vitamin K antagonists oral anticoagulants ornonvitamin K antagonists oral anticoagulants or DOAC or direct oral anticoagulants or Apixaban or Dabigatran or Rivaroxaban or Edoxaban or factor Xa inhibitor or TSOAC or TOAC or fxa inhibitor or direct thrombin inhibitor).mp. |
| 5 | exp apixaban/ or exp dabigatran/ or exp rivaroxaban/ or edoxaban/ or rivaroxaban |
| 6 | 4 or 5 [treatment] |
| 7 | 3 and 6 [condition and treatment] |
|  | **Study terms** |
| 8 | clinical study/ |
| 9 | case control study/ |
| 10 | family study/ |
| 11 | longitudinal study/ |
| 12 | retrospective study/ |
| 13 | prospective study/ |
| 14 | randomized controlled trial/ |
| 15 | 13 not 14 |
| 16 | cohort analysis/ |
| 17 | (cohort adj stud$).mp. |
| 18 | (Case control adj stud$).tw. |
| 19 | (follow up adj stud$).tw. |
| 20 | (observational adj stud$).tw. |
| 21 | (epidemiologic$ adj stud$).tw. |
| 22 | (cross sectional adj stud$).tw. |
| 23 | (registr$ or register$).tw. |
| 24 | database$.tw |
| 25 | ("real-world" or "real world" or "real-life" or "real life" or RWE or RWD).tw. |
| 26 | Or/8-25 [study] |
| 27 | 7 and 26 [condition and treatment and study] |
| 28 | Remove duplicates from 27 |
| 29 | limit 28 to english language  |
| 30 | limit 29 to yr="2011 -Current" |

## Supplementary Table S3. Details of search strategy used in Ovid MEDLINE® search (01 January 2011–04 May 2017).

|  |
| --- |
| **SEARCH TERMS** |
|  | **Condition terms** |
| 1 | (atrial fibrillation or AF or NVAF or AVAF).mp. |
| 2 | Atrial Fibrillation/ |
| 3 | 1 or 2 [condition] |
|  | **Treatment terms** |
| 4 | (new oral anticoagulants or novel oral anticoagulants or NOAC or non-vitamin K antagonists oral anticoagulants ornonvitamin K oral anticoagulants or DOAC or direct oral anticoagulants or Apixaban or Dabigatran or Rivaroxaban or Edoxaban or factor Xa inhibitor or TSOAC or TOAC or fxa inhibitor or direct thrombin inhibitor).mp. |
| 5 | exp Dabigatran/ or exp Rivaroxaban/ or Apixaban/ or Edoxaban/ or Factor Xa Inhibitors/ |
| 6 | 4 or 5 [treatment] |
| 7 | 3 and 6 [condition and treatment] |
|  | **Study terms** |
| 8 | Epidemiologic studies/ |
| 9 | exp case control studies/ |
| 10 | exp cohort studies/ |
| 11 | Case control.tw. |
| 12 | (cohort adj stud$).tw. |
| 13 | cohort analy$.tw. |
| 14 | (follow up adj stud$).tw. |
| 15 | (observational adj stud$).tw. |
| 16 | Longitudinal.tw. |
| 17 | Retrospective.tw. |
| 18 | cross sectional studies.tw. |
| 19 | Cross-sectional studies/ |
| 20 | (registr$ or register$).tw. |
| 21 | database$.tw. |
| 22 | ("real-world" or "real world" or "real-life" or "real life" or RWE or RWD).tw.  |
| 23 | or/8-22 [study terms] |
| 24 | 7 and 23 [condition and treatment and study] |
| 25 | remove duplicates from 24 |
| 26 | limit 25 to English language |
| 27 | limit 26 to yr="2011 -Current" |

## Supplementary Table S4. Details of search strategy used in NHS Economic Evaluation Database (01 January 2011–31 December 2015).

|  |
| --- |
| **SEARCH TERMS** |
|  | **Condition terms** |
| 1 | (atrial fibrillation or AF or NVAF or AVAF).af. |
| 2 | exp Atrial Fibrillation/ |
| 3 | 1 or 2 [condition] |
|  | **Treatment terms** |
| 4 | (new oral anticoagulants or novel oral anticoagulants or NOAC or non-vitamin K antagonists oral anticoagulants or nonvitamin K antagonists oral anticoagulants or DOAC or direct oral anticoagulants or Apixaban or Dabigatran or Rivaroxaban or Edoxaban or factor Xa inhibitor or TSOAC or TOAC or fxa inhibitor or direct thrombin inhibitor).af. |
| 5 | exp Factor Xa/ |
| 6 | 4 or 5 [treatment] |
| 7 | 3 and 6 [condition and treatment] |
| 8 | limit 7 to yr="2011 -Current" |